© 2018 Elsevier Inc. Purpose/Objective: Radium-223 prolongs survival and decreases symptomatic skeletal events in men with metastatic castrate-resistant prostate cancer and is indicated in patients with painful bone metastases. However, pain responses are rarely reported and often asked about by patients. Further, patients and their physicians are concerned about a lack of pain response portending a poor treatment response and may be inclined to change systemic therapies before completing 6 cycles. We evaluated the likelihood and time course of pain response, potential predictors of response, and its prognostic value in patients receiving radium-223. Materials and Methods: We reviewed the charts of patients who received radium-223 in our de...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136309/1/pros23286.pdfhttps://deepblue...
Painful bone metastases are common in prostate cancer, with current treatments including non-steroid...
Ra, a targeted a-therapy, is approved for the treatment of patients with metastatic castration-resis...
© 2018 Elsevier Inc. Purpose/Objective: Radium-223 prolongs survival and decreases symptomatic skele...
PURPOSE: To investigate the dose-response relationship and pain-relieving effect of radium-223, a...
Giandomenico Roviello,1 Rosj Gallicchio,2 Giovanni Bozza,1 Maria Grazia Rodriquenz,1 Michele Aieta,1...
Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair q...
BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium...
Objective. Bone secondary localizations from metastatic castration-resistant prostate cancer are ass...
Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall surv...
BACKGROUND: Radium-223 (223Ra) chloride, an alpha emitter, has been shown to improve overall surviva...
Background Bone metastases frequently cause skeletal events in patients with metastatic castration-...
Radiopharmaceuticals previously used to treat patients with metastatic castrate-resistant prostate c...
Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic cas...
# The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Metast...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136309/1/pros23286.pdfhttps://deepblue...
Painful bone metastases are common in prostate cancer, with current treatments including non-steroid...
Ra, a targeted a-therapy, is approved for the treatment of patients with metastatic castration-resis...
© 2018 Elsevier Inc. Purpose/Objective: Radium-223 prolongs survival and decreases symptomatic skele...
PURPOSE: To investigate the dose-response relationship and pain-relieving effect of radium-223, a...
Giandomenico Roviello,1 Rosj Gallicchio,2 Giovanni Bozza,1 Maria Grazia Rodriquenz,1 Michele Aieta,1...
Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair q...
BACKGROUND: We sought to identify potential clinical variables associated with outcomes after radium...
Objective. Bone secondary localizations from metastatic castration-resistant prostate cancer are ass...
Radium-223 dichloride (Ra-223) is the first bone-targeting agent showing improvement in overall surv...
BACKGROUND: Radium-223 (223Ra) chloride, an alpha emitter, has been shown to improve overall surviva...
Background Bone metastases frequently cause skeletal events in patients with metastatic castration-...
Radiopharmaceuticals previously used to treat patients with metastatic castrate-resistant prostate c...
Introduction: Radium-223 (223Ra) improves symptoms and survival in patients with bone metastatic cas...
# The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Metast...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136309/1/pros23286.pdfhttps://deepblue...
Painful bone metastases are common in prostate cancer, with current treatments including non-steroid...
Ra, a targeted a-therapy, is approved for the treatment of patients with metastatic castration-resis...